Back to Type 2 Diabetes
NCT01106625
NCT01106625
Who may be able to join
Who might be able to join this trial:
- You must have been diagnosed with type 2 diabetes and currently be taking two specific diabetes medications: metformin and a sulphonylurea (a type of diabetes pill).
- Your HbA1c (a blood test showing average blood sugar levels over the past few months) must be between 7% and 10.5%.
- Your fasting blood sugar level (measured after not eating) must be below 270 mg/dL (15 mmol/L).
Who may not be able to join:
- You may not be eligible if you have a history of a serious diabetes complication called diabetic ketoacidosis, type 1 diabetes, a pancreas or beta cell transplant, diabetes caused by a pancreas condition or surgery, or if you have had a severe low blood sugar episode in the 6 months before joining the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Janssen Research & Development, LLC
Registry
clinicaltrials_gov
Start date
1 May 2010
Est. completion
1 September 2011
Where this trial is recruiting
🇦🇺 Australia
🇧🇪 Belgium
🇫🇷 France
Guatemala
🇭🇺 Hungary
🇮🇱 Israel
🇲🇽 Mexico
Puerto Rico
🇷🇺 Russia
🇪🇸 Spain
🇬🇧 United Kingdom
🇺🇸 United States
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in HbA1c From Baseline to Week 26
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.